Core Viewpoint - The Schall Law Firm is investigating First Citizens BancShares, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Financial Performance - First Citizens reported its Q4 2025 financial results on January 23, 2026, with an efficiency ratio of 64.5%, which was below analyst expectations [2]. - The company provided a weaker outlook for the upcoming year, indicating deteriorating revenues and net interest income projections that did not meet market expectations [2]. - Following the release of these results, shares of First Citizens fell by nearly 8.5% on the same day [2].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Carvana Co. regarding violations of federal securities laws and unlawful business practices [1][2]. Investigation Details - A report by Gotham City Research alleged that Carvana's reported profitability is based on undisclosed related-party transactions with DriveTime and Bridgecrest, claiming that DriveTime incurred over $1 billion in cash losses while leveraging 20x to 40x EBITDA to support Carvana's earnings [2] - Following the report, Carvana's share price dropped by $67.68, approximately 14.2%, from $477.72 on January 27, 2026, to close at $410.04 on January 28, 2026 [2]. Next Steps - Investors who purchased or acquired Carvana shares and experienced losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims [3]. About Bragar Eagel & Squire, P.C. - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in various types of litigation, including securities and consumer protection [4].

Core Viewpoint - Wealthfront Corporation is under investigation for potential violations of federal securities laws and other unlawful business practices following its IPO and subsequent financial performance [1][5]. Group 1: IPO and Initial Performance - Wealthfront completed its Initial Public Offering (IPO) on December 12, 2025, offering 34,615,384 shares at a price of $14.00 per share [2]. - The company's first quarterly results as a publicly traded entity, published on January 12, 2026, revealed net deposit outflows of $208 million, a significant decline from the $874 million inflows during the same period the previous year [3]. Group 2: Management Insights and Stock Performance - CEO David Fortunato attributed the decline in deposits to falling interest rates and highlighted the strategic importance of Wealthfront's new home-lending business as a protective measure against further declines [3]. - Fortunato disclosed that he holds a 95.1% stake in Wealthfront's home-lending business and mentioned the possibility of revising the ownership structure [3]. - Following the earnings call, Wealthfront's share price dropped by $2.12, or approximately 16.8%, from $12.59 to $10.47 [3]. - Since the IPO, Wealthfront's share price has decreased by $5.20, or about 37.1%, closing at $8.80 on January 20, 2025 [4].

Core Viewpoint - Hagens Berman is investigating Zimmer Biomet Holdings, Inc. due to concerns over the company's previously stated "high confidence" in its 2025 revenue targets following significant operational disruptions and revenue misses in emerging markets [1][4]. Group 1: Investigation Details - The investigation focuses on whether Zimmer Biomet's senior management misled investors about the stability of its international business, particularly after assurances of strong growth in August 2025 [2][4]. - Following the company's November 5, 2025 disclosure of distributor order cancellations in emerging markets and a revenue miss in Latin America, Zimmer Biomet's stock fell by 15%, significantly impacting its market value [2][6]. Group 2: Management Statements and Market Reaction - In August 2025, management expressed "very high" confidence in achieving a year-over-year organic revenue growth forecast of 3.5% to 4.5%, which contributed to a 7% increase in share price on that day [6]. - The November 5 earnings call revealed that the actual year-over-year organic revenue growth was only 5%, leading to a reduction in the growth forecast to 4% and acknowledgment of emerging markets as a headwind [6]. Group 3: Leadership Changes and Future Guidance - Zimmer Biomet announced leadership and governance changes in response to the challenges faced in international markets throughout 2025 [6]. - CEO Ivan Tornos stated the need for more measured external commentary following the scrutiny from analysts, indicating a shift in the company's communication strategy [6].

Core Viewpoint - Scott+Scott Attorneys at Law LLP is investigating potential misleading statements and omissions by Beta Bionics, Inc. that may have violated federal securities laws, following a significant drop in the company's stock price after disappointing financial results were announced [1][3]. Company Overview - Beta Bionics is a medical device company focused on designing, developing, and commercializing solutions for individuals with diabetes who require insulin [2]. Financial Performance - On January 8, 2026, Beta Bionics reported preliminary, unaudited topline financial results for Q4 2025, indicating at least 5,581 new patient starts, which fell short of the consensus expectation of 6,078 [3]. - Following the announcement, Beta Bionics' stock price decreased by approximately $11.85, or 37%, closing at $20.14 on January 9, 2026 [3].

Core Viewpoint - Blue Owl Capital Inc. is facing allegations of issuing materially false and misleading statements regarding its business operations and liquidity issues during the class period from February 6, 2025, to November 16, 2025 [1] Group 1: Allegations and Issues - The complaint alleges that Blue Owl was experiencing significant pressure on its asset base due to redemptions from business development companies [1] - As a result of these pressures, the company was facing undisclosed liquidity issues [1] - The company is likely to limit or halt redemptions of certain business development companies due to these liquidity concerns [1] - Defendants' positive statements about the company's business, operations, and prospects were materially misleading and lacked a reasonable basis [1] Group 2: Shareholder Actions - Shareholders who purchased shares of OWL during the specified class period are encouraged to contact the Gross Law Firm regarding possible lead plaintiff appointment [1] - The deadline for shareholders to register for the class action is February 2, 2026 [2] - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive status updates throughout the lifecycle of the case [2]

Group 1 - The Schall Law Firm is investigating claims on behalf of investors of Wealthfront Corporation for potential violations of securities laws [1] - The investigation is centered on whether Wealthfront issued false or misleading statements and failed to disclose important information to investors [2] - Following the release of quarterly earnings, Wealthfront's shares dropped by 14% due to reported softening in asset flows during November and December [2]

Core Viewpoint - Scott+Scott Attorneys at Law LLP is investigating Corcept Therapeutics Incorporated for potentially issuing misleading statements and failing to disclose material information to investors, which may violate federal securities laws [1]. Company Overview - Corcept Therapeutics is a pharmaceutical company focused on discovering, developing, and commercializing drugs for severe metabolic, psychiatric, and oncologic disorders [2]. Recent Developments - On December 31, 2025, Corcept announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant, indicating that the FDA could not determine a favorable benefit-risk assessment without additional evidence of effectiveness from Corcept [3]. - Following the FDA's announcement, Corcept's stock price dropped over 50%, closing at $34.80 per share on December 31, 2025 [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SLM Corporation due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's financial health and delinquency rates [2][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in SLM between July 25, 2025, and August 14, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against SLM, with a deadline of February 17, 2026, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [7]. Group 2: Allegations Against SLM - The complaint alleges that SLM and its executives made false and misleading statements regarding the company's financial stability, particularly about early-stage delinquencies and the effectiveness of loss mitigation programs [5]. - A report from TD Cowen indicated that July 2025 delinquencies increased by 49 basis points month-over-month, contradicting SLM's claims of normal seasonal trends [6]. - Following the TD Cowen report, SLM's stock price dropped by $2.67 per share, or 8.09%, closing at $30.32 on August 15, 2025 [6]. Group 3: Firm Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

Company Overview - Ventyx Biosciences develops oral therapies targeting autoimmune, inflammatory, and neurodegenerative diseases [3] Allegations of Wrongdoing - Edelson Lechtzin LLP is investigating Ventyx for potential violations of federal securities laws due to allegations of misleading business information [1] - On December 2, 2025, Ventyx announced a delay in the Phase 2 trial of VTX2735 for recurrent pericarditis, with topline results now expected in Q1 2026. This delay is attributed to testing a new once-daily formulation and expanding the study into Canada, the EU, and the UK [4] - Following the announcement, Ventyx's stock price dropped by $1.44 per share, or 15.35%, closing at $7.94 per share on the same day [4]